Flyout Menu

Designing Scalable, Regulatory-Ready Processes for Small Molecule NCEs

Consult an expert

Sai Life Sciences advances small molecule NCE programs through disciplined process design and development, translating discovery chemistry into scalable, well-characterized synthetic routes that support clinical progression and future commercialization.

By integrating process chemistry, analytical science, particle science, and process engineering, we establish robust operating windows, impurity control strategies, and process safety frameworks early in development. This integrated and science-led approach reduces scale-up risk, strengthens process understanding, and enables seamless transition into GMP manufacturing.

Our Capabilities

Discovery Process Chemistry

Translation of discovery chemistry into scalable synthetic routes through route scouting, feasibility evaluation, and early impurity mapping.

Process Development

Optimization of synthetic pathways to establish robust operating windows, controlled impurity profiles, and reproducible performance.

Analytical Development

Development and validation of analytical methods supporting process understanding, impurity control, and regulatory readiness.

Process Engineering

Application of engineering principles to scale-up strategy, process safety assessment, and equipment alignment for pilot and commercial readiness.

Particle Science & Engineering

Solid-state characterization, polymorph control, and particle engineering to ensure consistent material performance and downstream manufacturability.

Developability & Pre-formulations

Early-stage material assessment integrating physicochemical profiling and stability understanding to inform formulation and scale-up decisions.

The Sai Difference

Drug Substance Development at Sai is engineered to de-risk scale-up, align with regulatory expectations, and prepare processes for reliable GMP execution. We also bring together scientific depth, operational scale, and integrated discovery capabilities to advance programs efficiently.

Discovery to Development Continuity

Early alignment with process research and manufacturing minimizes transfer risk and supports scalable candidate progression.

Program Ownership and Governance

Integrated scientific leadership and unified program management ensure accountability across milestones.

Depth with Delivery Scale

300+ discovery programs delivered across therapeutic areas with experience advancing assets into the clinic.

Flexible Partnership Structures

Fee-for-service and FTE models aligned to portfolio strategy and long-term collaboration.